Levetiracetam is an antiepileptic used to treat partial, primary generalised, and myoclonic seizures. It is generally well tolerated with few drug interactions.
Also known as: keppra, briviact
DailyMed/FDA — Keppra; EMC-UK — Levetiracetam
DailyMed/FDA — Keppra; EMC-UK
Antiepileptic + antiepileptic: no clinically significant pharmacokinetic interaction.
Levetiracetam is not metabolised by CYP and does not significantly bind to plasma proteins. There is no pharmacokinetic interaction with phenytoin.
No specific monitoring required.
No dose adjustment required.
DailyMed/FDA; EMC-UK
No documented food or drink interactions.
50% excreted unchanged renally. Accumulation in renal impairment.
eGFR 30-50: reduce dose by 50%. eGFR <30: reduce by 75%. Haemodialysis: supplemental dose.
DailyMed/FDA; EMC-UK
Limited data. Observational studies do not show significant increase in malformations. Use with caution.
Insufficient data. Use only if benefit justifies risk.
Excreted in breast milk in low concentrations. May be used during breastfeeding with caution.
Insufficient data on effects on fertility.
DailyMed/FDA — Keppra; EMC-UK
Clinical and educational support tool. The information does not replace a medical prescription or the opinion of a qualified healthcare professional.
Antiepileptic activity via binding to synaptic vesicular protein SV2A. Effect on glutamatergic and GABAergic neurotransmission.
Selectively binds to SV2A (synaptic vesicular protein 2A), modulating neurotransmitter release. Does not act on conventional ion channels or receptors.
Rapid and complete oral absorption. Bioavailability: 100%. Food does not affect absorption. Peak: 1-2 h.
Not metabolised by CYP. Minimal renal hydrolytic metabolism (50% unchanged). Inactive metabolites.
6-8 h (adults), 4-6 h (children).
Medicines from the same therapeutic group (ATC classification) or the same pharmacological class.
